The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93.

Kyle, Robert A

The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93. [electronic resource] - Cancer May 2009 - 2155-64 p. digital

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

0008-543X

10.1002/cncr.24221 doi


Antineoplastic Combined Chemotherapy Protocols--adverse effects
Carmustine--adverse effects
Cyclophosphamide--administration & dosage
Disease-Free Survival
Female
Humans
Interferon Type I--administration & dosage
Male
Melphalan--adverse effects
Middle Aged
Multiple Myeloma--drug therapy
Prednisone--adverse effects
Recombinant Proteins
Survival Rate
Vincristine--adverse effects